Incyte | INCY - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 279.64M 36.37M 2026-06
Agenus USD 33.74M 468K 2026-03
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Alnylam Pharmaceuticals USD 992.69M 167.68M 2026-06
Amgen USD 5.87B 1.02B 2026-03
BioCryst Pharmaceuticals USD 214.41M 61.36M 2026-06
Biogen USD 2.12B 307M 2026-06
BioMarin Pharmaceutical USD 713.42M 142.21M 2026-06
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Eli Lilly USD 16.22B 301.7M 2026-03
Exelixis USD 608.03M 17.17M 2026-06
Gilead Sciences USD 6.8B 1.29B 2026-06
Incyte USD 1.57B 400.89M 2026-06
Ionis Pharmaceuticals USD 265M 22M 2026-06
MacroGenics USD 11.24M 19.87M 2026-03
Merck USD 12.09B 1.24B 2026-03
Moderna USD -566M 792M 2026-03
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 11.24B 1.18B 2026-06
Novartis USD 10.07B 758M 2026-03
Pfizer USD -248M 11.29B 2026-06
PTC Therapeutics USD 232.94M 84.56M 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 3.71B 778.2M 2026-06
Sarepta Therapeutics USD 251.15M 370.2M 2026-06
Ultragenyx Pharmaceutical USD 180M 74M 2026-06
Vertex Pharmaceuticals USD 2.84B 242.4M 2026-06